stockrow
Friday 6 November 2026
Export TCMD’s income statement to Excel — free account
Tactile Systems Technology, Inc.
TCMD Healthcare Medical Devices
Tactile Systems Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $329.5 million, up 12.5% from fiscal 2024.
- Revenue
- +7.12%
- EPS
- −14.5%
- Free cash flow
- +23.8%
Quarter to September 2026, against a year earlier
26.07
0.30
−1.14%
Follow TCMD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
34.12 | 29.03 | 27.07 | 21.30 |
P/S ratio |
2.01 | 1.72 | 1.93 | 1.42 | |
P/FCF ratio |
16.47 | 15.08 | 25.32 | 17.48 | |
P/Operating CF |
38.35 | (1,739.00) | 207.54 | 42.12 | |
P/B ratio |
3.03 | 2.71 | 3.02 | 2.22 | |
Price to Tangible BV |
4.46 | 4.33 | 4.84 | 3.50 | |
EV/Sales |
1.78 | 1.52 | 1.75 | 1.22 | |
EV/EBITDA |
16.31 | 13.41 | 14.67 | 10.77 | |
EV/Operating CF |
13.68 | 12.39 | 20.04 | 13.55 | |
EV/FCF |
14.55 | 13.33 | 22.96 | 15.12 | |
Quick Ratio |
3.49 | 3.57 | 3.37 | 2.92 | |
Current Ratio |
4.03 | 4.24 | 4.12 | 3.51 | |
Net Debt/EBITDA |
(4.86) | (858.96) | (9.82) | (7.92) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.15 | 1.24 | 1.27 | 1.30 | |
Operating CF/Net income |
1.63 | 0.19 | 0.42 | 1.67 | |
Capex/Depreciation |
(0.36) | (0.51) | (0.73) | (0.34) | |
Interest Coverage |
1,706.82 | (54.79) | 359.26 | 479.55 | |
Research and Development Expense of Revenue |
2.44% | 3.69% | 2.92% | 2.73% | |
Selling, General and Administrative Expense of Revenue |
57.05% | 74.10% | 64.61% | 62.81% | |
Intangible Assets out of Total Assets |
0.26 | 0.30 | 0.30 | 0.29 | |
Share Based Compensation of Revenue |
2.45% | 2.36% | 2.64% | 2.59% | |
Graham Net Nets |
0.17 | 0.17 | 0.15 | 0.20 | |
Graham Number |
13.53 | 13.98 | 15.63 | 15.38 | |
Earnings Yield |
2.93% | 3.44% | 3.69% | 4.69% | |
Free Cash Flow Yield |
6.07% | 6.63% | 3.95% | 5.72% | |
Revenue per Share |
4.53 | 3.34 | 3.78 | 4.06 | |
Operating CF per Share |
0.76 | (0.01) | 0.14 | 0.53 | |
Capex per Share |
(0.03) | (0.04) | (0.06) | (0.03) | |
Free Cash Flow per Share |
0.73 | (0.05) | 0.09 | 0.50 | |
Cash per Share |
4.34 | 4.00 | 3.74 | 3.98 | |
Shareholders Equity per Share |
9.57 | 9.66 | 9.87 | 10.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.57 | 9.66 | 9.87 | 10.04 | |
Free Cash Flow |
16.72 | (1.17) | 1.94 | 11.38 | |
Working Capital |
124.21 | 116.83 | 119.35 | 119.28 | |
Capital Expenditures |
(0.58) | (0.83) | (1.32) | (0.60) | |
Net Current Asset Value |
110.13 | 98.59 | 101.77 | 102.74 | |
EV/EBIT |
20.01 | 16.14 | 17.48 | 12.96 | |
Capex to Sales |
0.01 | 0.01 | 0.02 | 0.01 | |
Price to Operating Income |
22.66 | 18.26 | 19.28 | 14.99 | |
| Other line items | |||||
Average Receivables |
44.41 | 37.55 | 38.80 | 43.05 | |
Average Payables |
5.31 | 7.17 | 7.97 | 9.89 | |
Average Inventory |
16.35 | 17.72 | 16.98 | 15.84 | |
Average Assets |
285.93 | 276.18 | 276.36 | 275.24 | |
Average Common Equity |
217.75 | 211.75 | 209.38 | 216.10 |
Columns are period end dates · fundamentals updated 5 Nov 2026